malvern semaglutide FDA Warns on Certain Forms of Compounded Semaglutide Weight Loss Injections &

Adding semaglutide or tirzepatide adds redundant GLP-1 (and GIP, in the case of tirzepatide) activity without new pathway coverage

Li welcomed this question, stating that his group was interested in investigating this same topic and that the next steps of their work will be to better characterize these mechanisms that may be resulting in alterations in urinary biochemistry

Fortunately, the identification and exploration of non-apoptotic cell death pathways, such as ferroptosis pathways, have opened up new opportunities for therapeutic interventions

The AASLD 2023 MASLD Practice Guidance does not yet address this DDI scenario specifically, because approved MASLD-targeted therapies using GCGR agonism were not available at the time of publication